Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis

Sorrel E Wolowacz; David A Cameron; Helen C Tate; Adrian Bagust

doi:10.1200/JCO.2006.10.4190

Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis

Sorrel E Wolowacz, David A Cameron, Helen C Tate, Adrian Bagust

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

To estimate the cost effectiveness of TAC (docetaxel, doxorubicin, and cyclophosphamide) compared with FAC (fluorouracil, doxorubicin, and cyclophosphamide) when administered as adjuvant therapy to women with node-positive early breast cancer in the United Kingdom (UK), both with and without primary prophylaxis with granulocyte colony-stimulating factor (G-CSF).

Original language	English
Pages (from-to)	925-33
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	26
Issue number	6
DOIs	https://doi.org/10.1200/JCO.2006.10.4190
Publication status	Published - 2008

Keywords / Materials (for Non-textual outputs)

Antineoplastic Combined Chemotherapy Protocols
Axilla
Breast Neoplasms
Chemotherapy, Adjuvant
Cost-Benefit Analysis
Cyclophosphamide
Decision Trees
Disease-Free Survival
Doxorubicin
Female
Fluorouracil
Granulocyte Colony-Stimulating Factor
Great Britain
Humans
Kaplan-Meier Estimate
Lymph Nodes
Lymphatic Metastasis
Markov Chains
Neoplasm Staging
Neutropenia
Protective Agents
Quality-Adjusted Life Years
Taxoids

Access to Document

10.1200/JCO.2006.10.4190

Cite this

@article{506ac4f128ea47f38baeb5e9a18f0b37,

title = "Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis",

abstract = "To estimate the cost effectiveness of TAC (docetaxel, doxorubicin, and cyclophosphamide) compared with FAC (fluorouracil, doxorubicin, and cyclophosphamide) when administered as adjuvant therapy to women with node-positive early breast cancer in the United Kingdom (UK), both with and without primary prophylaxis with granulocyte colony-stimulating factor (G-CSF).",

keywords = "Antineoplastic Combined Chemotherapy Protocols, Axilla, Breast Neoplasms, Chemotherapy, Adjuvant, Cost-Benefit Analysis, Cyclophosphamide, Decision Trees, Disease-Free Survival, Doxorubicin, Female, Fluorouracil, Granulocyte Colony-Stimulating Factor, Great Britain, Humans, Kaplan-Meier Estimate, Lymph Nodes, Lymphatic Metastasis, Markov Chains, Neoplasm Staging, Neutropenia, Protective Agents, Quality-Adjusted Life Years, Taxoids",

author = "Wolowacz, {Sorrel E} and Cameron, {David A} and Tate, {Helen C} and Adrian Bagust",

year = "2008",

doi = "10.1200/JCO.2006.10.4190",

language = "English",

volume = "26",

pages = "925--33",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "6",

}

TY - JOUR

T1 - Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis

AU - Wolowacz, Sorrel E

AU - Cameron, David A

AU - Tate, Helen C

AU - Bagust, Adrian

PY - 2008

Y1 - 2008

N2 - To estimate the cost effectiveness of TAC (docetaxel, doxorubicin, and cyclophosphamide) compared with FAC (fluorouracil, doxorubicin, and cyclophosphamide) when administered as adjuvant therapy to women with node-positive early breast cancer in the United Kingdom (UK), both with and without primary prophylaxis with granulocyte colony-stimulating factor (G-CSF).

AB - To estimate the cost effectiveness of TAC (docetaxel, doxorubicin, and cyclophosphamide) compared with FAC (fluorouracil, doxorubicin, and cyclophosphamide) when administered as adjuvant therapy to women with node-positive early breast cancer in the United Kingdom (UK), both with and without primary prophylaxis with granulocyte colony-stimulating factor (G-CSF).

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Axilla

KW - Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - Cost-Benefit Analysis

KW - Cyclophosphamide

KW - Decision Trees

KW - Disease-Free Survival

KW - Doxorubicin

KW - Female

KW - Fluorouracil

KW - Granulocyte Colony-Stimulating Factor

KW - Great Britain

KW - Humans

KW - Kaplan-Meier Estimate

KW - Lymph Nodes

KW - Lymphatic Metastasis

KW - Markov Chains

KW - Neoplasm Staging

KW - Neutropenia

KW - Protective Agents

KW - Quality-Adjusted Life Years

KW - Taxoids

UR - http://www.scopus.com/inward/record.url?scp=39749201899&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.10.4190

DO - 10.1200/JCO.2006.10.4190

M3 - Article

C2 - 18281666

SN - 1527-7755

VL - 26

SP - 925

EP - 933

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 6

ER -

Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Other files and links

Fingerprint

Cite this